

# Specific Aims

We propose to improve prediction and prevention of respiratory failure and death in hospitalized patients by integrating complex Bayesian hierarchical modeling into data imputation, patient triage and treatment implementation in electronic medical record based (EMR) surveillance.

**Severe acute respiratory failure (ARF) requiring mechanical ventilation leads to increased mortality,** increased cognitive and functional impairment. EMR surveillance can identify hospitalized patients at risk, days before their deteriorating conditions are typically recognized; earlier initiation of preventive interventions can reduce morbidity, mortality and expenses: My mentor Dr. Gong is leading a two phase pragmatic trial: APPROVE, phase 1, develops a classical algorithm to identify patients at risk; PROOFCheck, phase 2, aims to improve outcomes by triggering an individualized prevention checklist for patients identified as at risk by APPROVE.

**Our Bayesian model may outperform the classical prediction model thanks to partial pooling.** We propose to fit a more complex hierarchical Bayesian prediction algorithm, (1) by allowing model parameters to vary between patients, between medical floors, services or institutions and (2) by modeling temporal effects, e.g. institutional learning during trial implementation. We will outperform Dr. Gong's classical prediction algorithm by (a) partial pooling and (b) modeling the rich spatial and temporal organization of our electronic medical records more realistically: Patients treated by the same team, in similar settings will show similar clinical trajectories and responses. Especially in the subset with sparse or missing data, precision and accuracy of parameter estimates will be improved by partial pooling, because they are informed by data from all the other patients.

**Incomplete data limits prediction algorithms, poor compliance compromises effective interventions** and outcomes research. With my co-mentor Dr. Hall, I will advance Bayesian data imputation using auxiliary data, a novel approach to overcome issues with missing at random assumptions. Seasonal effects, changing population characteristics or provider behavior may limit prediction accuracy. We will update our model continuously with new patient information, adjust for seasonal effects and institutional learning. Last but not least, effective therapy only works if implemented; we will investigate what predicts provider compliance with our EMR-triggered alerts.

**Implementation of Bayesian hierarchical modeling can be computationally challenging for Big Data.** My co-mentor Dr. Gelman is leading the NSF-funded development of STAN. STAN's novel Hamiltonian Markov Chain Monte Carlo algorithm achieves much faster convergence and parameter estimation. With my exceptional and multidisciplinary team of mentors, I will integrate innovative approaches to data imputation with complex hierarchical prediction models to form a "real time" EMR-based clinical decision tool. We will overcome current limitations in Bayesian computational implementation for multi-center EMR-based outcomes research. This integration of pioneering statistical modeling with pragmatic EMR-surveillance constitutes the unique innovation of my proposal.

**Hypothesis:** *Hierarchical Bayesian modeling compared to the classical model improves imputation, prediction, prevention and compliance analysis in a pragmatic trial to prevent respiratory failure in hospitalized patients.*

## Specific aims:

### **Aim 1: To improve incomplete data imputation and early prediction of acute respiratory failure.**

**SA 1a:** To build a pragmatic EMR based hierarchical Bayesian model implemented in the ultra-fast statistical software Stan to predict a composite outcome [death or prolonged mechanical ventilation > 48 hours] in our Montefiore Medical Center inpatients and compare it with the existing classical (frequentist) algorithm.

**SA 1b:** To further develop Bayesian data imputation algorithms of missing clinical data using auxiliary data, to identify auxiliary measure properties (ceiling, floor and threshold effects), to integrate imputation and prediction in one coherent hierarchical Bayesian model and compare it to the classical algorithm by Dr. Gong.

### **Aim 2: To model temporality (institutional learning, seasons) and investigate provider compliance.**

**SA 2a:** To update our model continuously with new incoming patients to reflect their changing risk profile and to model institutional learning and temporal effects like seasons and endemics.

**SA 2b:** To investigate patient and provider characteristics as drivers of poor provider compliance in PROOFCheck, Dr. Gong's pragmatic trial, to inform the ongoing PROOFCheck trial implementation, refocus our retraining efforts and to explore the individualization of preventive interventions using EMR-context.

# Research Plan

## A. Significance

### Respiratory failure in hospitalized patients can be predicted and should be prevented.

Acute respiratory failure (ARF) requiring mechanical ventilation is common in hospitalized patients, consuming a disproportionate amount of health care resources in the USA [2]. Short term mechanical ventilation can be life saving, but prolonged mechanical ventilation often leads to multi-organ failure and death in a third of patients [2, 3].

Most research focuses on *established* respiratory failure in the ICU, while detectable clinical signs and symptoms often herald the impending respiratory decompensation much earlier [4]. Dr. Gong co-developed the LIPS score to identify patients at high risk for the development of Adult Respiratory Distress Syndrome (ARDS) in the emergency department [5], which proved equally able to discriminate the 587 patients in the cohort who progressed to severe ARF requiring > 48 hrs of mechanical ventilation. She also demonstrated that predictive scores deteriorate as early as 24-48 hours before ICU admission [Figure 1] [1]; but such ominous signs are either not recognized or not acted upon [6, 7]. Early interventions (e.g appropriate antibiotic therapy, diuretics and chest physiotherapy) and preventive measures (e.g. head elevation) would be able to stop or reverse the clinical deterioration and/or prevent progression to multiple organ failure and prolonged mechanical ventilation or at least attenuate the subsequent clinical course [8, 9, 10, 11].




Figure 1: Deterioration of the Sequential Organ Failure Assessment score (SOFA) can be detected 24 to 48 hours before clinical deterioration leads to ICU admission [1].

**A pragmatic trials to predict and prevent mortality from respiratory failure in hospitalized patients.** My mentor Dr. Gong is leading a NHLBI-funded multi-center cluster randomized pragmatic trial in two phases. (1) the first phase APPROVE aims to identify patients at risk by building classical logistic regression models based on electronic medical records (EMR) to Accurately Predict PROlonged Ventilation. (2) In the second phase PROOFCheck, identification of a patients at high risk triggers a decision support tool and bundled checklist of processes of care known to be beneficial in critically ill patients to PRevent Organ Failure. CITE CLINICAL TRIALS.GOV. The hypothesis is that for the patients identified as at high risk for prolonged respiratory failure or death in APPROVE, the early implementation of a checklist of preventive measure (PROOFCheck), reduces severity of organ failure, mortality and duration of mechanical ventilation.

**Electronic medical records are an eminent example of richly structured and correlated Big Data** and hold enormous promise for outcomes research [12, 13], exemplified by Dr. Gong's pragmatic trial. However, large electronic medical data sets are not just bigger in that there are more instances of the same thing, (e.g. more patients would make data analysis only easier). Rather, there is more breadth to the data, and in the case of pragmatic trials, more heterogeneity, more subgroups, locations, or time granularity than is currently being modeled, more frequent and detailed measurements than can easily be incorporated into classical models. This currently limits the scientific hypotheses and clinical inferences, that can be explored and evaluated. In Dr. Gong's pragmatic trial in particular, we desire more fine-grained information on the predictions to individualize prevention.

**We can individualize prevention targeting patients at risk.** Preventive measure, for example goal targeted resuscitation, decrease respiratory failure requiring mechanical ventilation, when they are initiated early [10]. However, an indiscriminate approach to prevention of respiratory failure in hospitalized patients will be ineffective, because only one in 30 hospitalized adults requires mechanical ventilation. Secondly, individualizing preventive and therapeutic measures specifically based on patient characteristics will be more efficient in preventing potentially irreversible end organ damage, while also leading to improved compliance by providers and cost effectiveness. So how can we improve and individualize prediction and prevention?

## Bayesian hierarchical modeling is transformative for EMR based prediction.

**Bayesian methods are old, but novel in EMR surveillance.** Reverend Thomas Bayes (Portrait in Fig.1)[14] formulated the Bayes theorem already in 1763 as an alternative statistical model. With a well developed theory, Bayesian methods are only novel in so far as they were rarely used in medical research until computers and Markov Chain Monte Carlo algorithms became widely available in the 1990s, leading to an expansion of applied Bayesian work [15, 16], more recently also in Big Data [17]. Past constraints in computational implementation have largely been overcome, except maybe for very large complex data sets like EMRs. We are not aware of any Bayesian hierarchical prediction model based on large EMRs to date. However, now ultra-fast Hamiltonian Monte Carlo algorithms [18] and clever statistical formulation or transformation allow to push the boundaries of computability, also for very large EMR data sets [19].



Figure 2: Thomas Bayes formulated the Bayes Theorem, published in a posthumous paper in 1763. [14].

**A too brief introduction to Bayesian inference and its computational implementation.** In Bayesian inference, prior information is combined with new data to yield an updated posterior estimate for the probability of a hypothesis [20]. The Bayesian approach is hence analogous to clinical decision-making [16]. Physicians continuously update their preliminary diagnosis as new information comes in. Prior belief in a diagnosis may be weakened by new laboratory information, leading to an alternative disease hypothesis; or new lab information may reaffirm the initial diagnosis. [21]. Bayesian inference for more complex (hierarchical) models can often not be derived analytically; instead we calculate numerical approximations of the multi-dimensional integrals to obtain the posterior distributions of the parameters of interest. In technical terms, Markov Chain Monte Carlo (MCMC) based Bayesian inference methods sample from a posterior probability distribution after building a Markov chain. In lay terms, MCMC simulation replaces intractable analytical integration with empirical summaries of samples from the posterior distribution [22]: *Instead of analyzing the odds, we simulate throwing the dice repeatedly.*

**Observations and outcomes in APPROVE and PROOFCheck will be nested hierarchically.** For example, repetitive oxygen saturation measurements will be similar in the same patients; the closer in time they are, the higher the correlation between repeated observations. Equally, patients seen by one and same hospitalist will tend to have similar outcomes, predicted by that physician's behavior and qualities. As an example, some physicians (or services) will follow a more liberal fluid management, others will emphasize early diureses; clearly this choice will summarily affect the respiratory failure risk of specifically those patients under this physician's care. Generally, physicians in large academic medical systems like ours are organized in services, which are integrated across wards, clustered in several hospitals. Consequently, the observations in our hospitalized patient cohort at the Albert Einstein College of Medicine, their outcomes and their propensity to respond to treatments, all are hierarchically nested; this requires more than just fitting well-known models at larger scales.

**Hierarchical models better exploit the fine-grained multilevel structures of electronic medical records** and will therefore optimally predict acute respiratory failure in our trial cohort. Fitting our predictive regression model, we would want the regression coefficients to vary by group (by service, by medical unit, by hospital), to realistically model the complex correlations seen in actual clinical practice. The number of parameters to estimate grows very quickly and so do the potential interactions. Reciprocally, even with very large data sets, the sample size in each subgroup will shrink rapidly; estimates using least squares or maximum likelihood will become noisy and thus often become essentially useless. One solution lies in hierarchical modeling, where we estimate hyper-parameters and hyper-hyper-parameters, to represent how lower level parameters vary across different groupings, as detailed in the approach under aim 1 [23]. Bayesian methods are particularly suited for flexible hierarchical modeling [24, 25]. With their inherent flexibility and robustness, Bayesian hierarchical models will outperform classical models for also for EMR- based prediction thanks to "partial pooling" [26].

**Prediction based on "partial pooling" outperforms the no-pooling and complete-pooling approach.** Employing hierarchical modeling for our prediction model will be more efficient, as can be shown mathematically or via cross-validation [19]. "No pooling" would be an alternative approach to estimate the model for each specific subset of interest separately. But addressing and exploring the complexity and granularity, the richness

of the EMR data would lead to far too many sub-classifications, thus too small samples in any given subgroup for useful inferences. "Complete pooling" or structural modeling constitutes the other extreme of the spectrum, but the implied hard constraints on the coefficients in different groups may lead to bias: we lose information, because we cannot learn from groups where we have more data. We choose the middle ground: Prediction using "partial pooling" or hierarchical modeling is especially effective for our richly organized EMR data, because the estimate of each individual parameter is simultaneously informed by data from all the other patients in our cohort, improving prediction in particular for subgroups with sparse data [27].

*We hypothesize that Bayesian hierarchical modeling may better identify hospitalized patients at risk for acute respiratory failure and prolonged mechanical ventilation than classical prediction algorithms.*

**Heterogeneous and incomplete clinical data may limit prediction and implementation.** Variables with strong predictive power in our model may not be recorded in all patients or may be missing for the time window needed for prediction, limiting development of the prediction algorithm, implementation of the therapeutic interventions and the trial itself. To improve prediction for cases with incomplete data, we can impute the missing data. Informative loss by non-ignorable incomplete data may bias risk prediction or may hamper the implementation of the prediction algorithm. Likelihood-based mixed effects models for incomplete data give valid estimates if and only if the data are ignorably missing; that is, the parameters for the missing data process are distinct from those of the main model for the outcome, and the data are missing at random (MAR) [28]. However, this is an unreasonable assumption for our electronic medical records, for example because physicians will request test based on the patients co-morbidity and current clinical conditions. Data will not be missing at random, instead incomplete data will be associated with predictors and outcomes; this could lead to biased imputations.

**Auxiliary data can be used to impute incomplete medical records.** Auxiliary data are additional information available in the form of variables known to be correlated with the missing data of interest [30]. In our data set we find that arterial blood gas oxygen tension is often unavailable for the prediction time window, because it was not requested by the physicians. In this case peripheral oxygen saturation and or oxygen therapy may be used to impute the peripheral arterial blood oxygen tension [Figure 3]. This approach avoids the perils associated with missing at random (MAR) assumptions, when fitting a non-ignorable missingness model [31].

Adding auxiliary variables not included in the main model for multiple imputation, in other words using additional information that is correlated with the missing outcome is an emerging approach to help correct bias [32, 33, 34], often relying on Bayesian methods for the multiple imputations approach [35, 36]; joint modeling and multiple imputations could both be used also to impute incomplete medical records [37]. The use of auxiliary data to impute incomplete patient records will improve the prediction model and facilitate smoother implementation of the algorithm into the clinical trial [29]. Moreover, auxiliary data imputation for incomplete electronic medical records is underdeveloped; methodologically, their development is an innovative hallmark of this proposal.

**Seasonal effects and institutional learning can bias risk prediction and can thwart implementation** or imperil the effectiveness of our efforts to mitigate the risks of severe respiratory failure in hospitalized patients. Like for any institution, the composition of the Montefiore Medical Center population, their co-morbidities and risk profiles change over time, altering which patient characteristics best predict severe adverse respiratory failure and mechanical ventilation. More importantly, we noted during the implementation phase of previous preventive trials, that providers learn, changing their behavior as a result of trial participation. As trials progressed providers implemented previously underutilized interventions more frequently even before they were prompted. We term this effect institutional learning. The transition of junior and senior providers through their training and to other institutions and new personnel joining the staff, may on the other hand led to these improvements being lost. Last




Figure 3: Incomplete data can hinder outcome prediction, but we can impute incomplete data from auxiliary information. For example, pneumonia (causing to low oxygen tension), may cause respiratory failure. If arterial blood gas results are missing, we can impute the oxygen tension from oxygen therapy and/or peripheral oxygen saturation. [29].

but not least, respiratory disease is affected by seasonal and secular effects; influenza prevalence for example is seasonal and characterized by major and minor epidemics. Seasons and epidemics will affect the predictive power of any model and hence also alter the risk profile of our patients over time. Institutional culture and individual provider behavior change in response to trials and quality improvements interventions; patient populations change over time. Respiratory patients are plagued by seasonal deterioration. These temporal, seasonal and secular effects will alter the predictors of risk in our model and affect its implementation. We will therefore include institutional learning, seasonal effects and continuously update our model with new patient data to account for said changes in the risk profile. The integration of institutional learning, secular and seasonal effects in a EMR-triggered prediction and prevention within one coherent (Bayesian) model is novel.

### **Analyzing and advancing implementation is decisive for outcome improvement and research.**

**Imperfect fidelity (poor provider compliance) is a major concern also in our PROOFCheck trial,** just as non-compliance is a major obstacle to the effective delivery of health care and improved outcomes in general [38]. The targeted interventions triggered by our EMR-prediction algorithm will only prevent respiratory failure if our physicians and nurses actually implement them. Improving fidelity of health care providers with evidence based interventions continues to be a challenge and is under-researched [39] and little is known on how to reproducing complex interventions (specially directed toward providers) to improve clinical outcomes [40]. As long as we do not understand what drives provider fidelity and patient compliance with the preventive measures proposed to our providers for their high risk patients [41], we ignore the best means to translate widely accepted interventions and new findings of outcomes research into practice [42]. We need to understand better what patient and/or provider characteristics hinder compliance with the triggered preventive checklist interventions to ensure care is in accordance with accepted evidence based best practices.

**We use a pragmatic trial to investigate heterogeneous provider fidelity with in clinical implementation.** Pragmatic trials like Dr. Gong's may result in valid estimates of effectiveness in more realistic health care scenarios [43, 44]; we will use her pragmatic trial data to investigate incomplete fidelity, heterogeneity and difficulty in clinical implementation. An example with problematic fidelity relevant for PROOFCheck is blood product management; transfusions increase the risk of acute severe respiratory failure with mechanical ventilation [45]; recent research led to consensus that overzealous and empiric transfusion of blood products leads to worse outcomes [46], acknowledging that untreated anemia also predicts poor outcome [47]; guidelines reflect this for over a decade [48], but years later, implementation of rational transfusion blood product management is sketchy and very heterogeneous across the nation [49]; not least because their complex algorithms can be difficult to follow. Weiss et al. demonstrated that direct prompting for best practices improves provider compliance in the ICU and outcomes such as duration of mechanical ventilation or length of stay [50]. We hypothesize that fidelity will be associated with certain provider and patient characteristics; their investigation will allow more focused re-education efforts and adaptation of the checklist implementation.

## **B. Innovation**

**Focus on prevention of critical adverse outcomes in hospitalized patients.** Changes in reimbursement give providers a stake in patient outcomes and led to a keen interest in the prediction and prevention of adverse event in hospitalized patients. It makes sense to focus early intervention on patients at high risk for poor outcomes. This project advances hierarchical Bayesian models to implement this paradigm shift in very large electronic medical records, triggering personalized interventions that drive outcome improvements. This is novel and has not been attempted to our knowledge.

**Improve imputation of incomplete electronic medical records.** Incomplete patient data, typical for actual clinical records can hinder the development and execution of our prediction algorithms and implementation of the pragmatic trial. We will further Bayesian methods to impute incomplete missing data from additional auxiliary data to overcome this limitation. Beyond improving prediction and patient outcomes in our clinical trial, the Bayesian methods we propose to develop can be employed to impute incomplete electronic medical records in other settings.

**Analyzing and understanding the drivers of poor provider compliance** in a multicenter pragmatic trial like Dr. Gong’s will be important for any EMR-based outcomes research or quality improvement, and will have implications beyond for any clinical trial, indeed for the implementation of evidence-based-medicine at large.

**Integrate advances in critical care with cutting edge computational statistics.** To often advances in statistical modeling and clinical science are worlds apart. We want to address a critical problem of scalability in Big Data inference, but are equally motivated by our practical use case. The strength of our proposal, is the integration of disparate disciplines, critical care and computational statistics.

**Summary of the impact**

We tackle a serious health care challenge by integrating advanced hierarchical modeling into a pragmatic clinical trial. Beyond improving morbidity and mortality from respiratory disease in hospitalized patients through improved prediction and prevention, we will develop new methods to impute incomplete electronic medical records from auxiliary data and scale Bayesian hierarchical models to use in large EMR data and will investigate drivers of poor provider compliance. Our proposal is unique and novel in its integration of cutting edge methods from clinical, statistical and computer science to fully realize the promise of Big Data in perioperative medicine.

**C. Approach**

My research project will be closely aligned with my mentor’s NIH-funded pragmatic two phase trial. Aim 1 will utilize the processed data of APPROVE to improve the prediction model and Aim 2 will use the data from the implementation of PROOFCheck to investigate fidelity of the providers with the EMR-triggered interventions.

**Aim 1: To improve early prediction of prolonged respiratory failure and death in hospitalized patients.**

*Hypothesis: The Integration of complex hierarchical Bayesian modeling and data imputation will improve prediction of severe respiratory failure in hospitalized patients compared to the classical statistical approach.*

**For specific aim 1a,** we will build a pragmatic EMR-based hierarchical Bayesian model to predict a composite outcome [mechanical ventilation prolonged beyond 48 hours or death] in hospitalized adult and compare our Bayesian approach with the existing frequentist algorithm used by Dr. Gong in her pragmatic trial.

**Population:** We will include all adults patients, admitted to the Montefiore Medical Center during the study period, excluding only those who are chronically ventilated at home or who have Do not resuscitate orders at the time of hospital admission (Table 1: Inpatient population at Montefiore Medical Center.) As part of APPROVE, the pragmatic trial by Dr. Gong described in detail under Significance, two 3-month, prospective, observational cohort studies are underway at several Albert Einstein College of medicine and Mayo Clinic Rochester and Florida sites; we will build our Bayesian hierarchical model based solely on Einstein patients: Patients from the first three months will serve as the fitting cohort, while the 2nd cohort will serve as the validation and test set.

Table 1: Table describing the population?

City	N <sup>a</sup>	%Silly
San Diego	289	41%
Seattle	262	32%
Galveston	261	15%
St Louis	269	7%
New York	271	4%
Baltimore	231	2%
Total	1,586	21%

<sup>a</sup>Inpatient population at Montefiore Medical Center.

**Predictors:** Many independent variables are candidates for potential inclusion into our Bayesian hierarchical model. From the multicenter LIPS study, clinical factors most closely associated with prolonged mechanical ventilation have already been identified [5]. We will consider these and additional time-invariant and time-variant demographic and clinical data. Examples for demographics are gender, age, medical service or ward, examples for physiological and clinical predictors are heart rate, blood pressure or lab tests, respectively. Certain predictors will require summary aggregations and (logarithmic) transformations to induce variance stability.

**Outcomes:** Our primary dichotomous outcome will be acute respiratory failure requiring mechanical ventilation longer than 48 hours. Outcomes are specified as positive for a) mechanical ventilation lasting longer than 48 hours or b) mechanical ventilation lasts less than 48 hours, but the patient died within 96 hours of the calculated



score. Patients that are not on prolonged ventilation within 96 hours or discharged alive from the hospital will be considered negative.

### Bayesian hierarchical modeling to reflect the nested structure of health care

We will build a Bayesian hierarchical multivariate logistic regression model of time-invariant and time-variant demographic, clinical and administrative variables. Our Bayesian hierarchical modeling will represent the multi-level nested structure of current health care, with levels for medical or surgical service the patient is under, the floor or ward where the patient is cared for, the institution the patient is admitted to. We will also consider other random effects for example for co-morbidity and other time-invariant patient specific descriptors. We illustrate this nested structure in a simple logistic model with hierarchical levels for patient, service and hospital.

**Patient level (1)** On the left, we model at the patient level, the probability  $\alpha$  that a patient will develop the dichotomous event  $Y$ , acute respiratory failure requiring mechanical ventilation, using arterial oxygen tension  $PaO_2$  as a predictor in a simple logistic regression model. However, patients are typically assigned to hospital services. Pulmonary service patients may have a lower baseline  $PaO_2$ , while surgical patients tend to have normal lung function.

$$Y \sim \text{Binom}(\alpha, n); \alpha = \text{inv\_log}(\beta_0 + \beta_1 * PaO_2) \quad (1)$$

**Service level (2)** On the left we develop our hierarchical model to allow different intercepts  $\beta_0$  representing the average  $PaO_2$  of patients in the various medical and surgical services estimating different service level mean intercepts  $\gamma_0$ . Under a medical service, smaller changes in  $PaO_2$  may be indicative of respiratory deterioration compared to a surgical service, where larger drop in arterial oxygen tension predicts outcome. We may allow the regression coefficient for the slope  $\beta_1$  to vary around different mean slopes  $\gamma_1$  at the service level.

$$\beta_0 \sim \text{Normal}(\gamma_0, \tau_{\beta_0}); \beta_1 \sim \text{Normal}(\gamma_1, \tau_{\beta_1}) \quad (2)$$

**Hospital level (3)** Some hospitals may cater to an economically disadvantaged population, which is sicker on average. To reflect this, we may model the mean intercept  $\gamma_0$  for the services hierarchically at the hospital level. Some hospitals are organized such that patients differ very much between services, other hospitals may have a more homogeneous patient distribution; this variation  $\tau_{\beta_1}$  of the mean slope  $\gamma_1$  within services at a given hospital can also be modeled to capture the variability of the predictive effect of lower  $PaO_2$ .

$$\gamma_0 \sim \text{Normal}(\delta, \zeta) \tau_{\beta_1} \sim \text{Normal}(\delta_{tau}, \kappa) \quad (3)$$

**In APPROVE, the compared frequentist prediction model will be build by Dr. Gong's statistical team** employing the published LIPS score [5] to identify hospitalized patients at risk for prolonged mechanical ventilation and death. The score at the selected start time will be used to determine the best cutoff score to identify the patients with the highest risk of developing prolonged mechanical ventilation.

**Data Acquisition** Data will be abstracted from a clinical data warehouse(see Environment and Resources). A multi-prong approach for capturing complete, longitudinal data in real-time, near real-time, or asynchronously from the EMR replica will be used. When possible, and where collection of additional complementary information is warranted, we will use the Retrieve Form for Data Capture IS THIS THE CORRECT REFERENCE?[51],an IHE30 IS THIS THE CORRECT REFERENCE? [52] standard for gathering new data within a user's current application environment (EMR in this case) to meet the requirements of an external system. Secured electronic data capture tools provided by the Montefiore Enterprise Clinical Research Management System will be used to streamline, quality control, normalize, and manage data collection and data entry efforts. A fully de-identified, study specific database of all study variables will be compiled for model development and validation. When subsequently patient data from additional regional medical centers are incorporated, site identifier variables will be obfuscated to blind investigators.




Figure 4: Hamiltonian MCMC uses momentum to optimize the next proposal. The higher momentum of the current position (black dot) is indicated in the top panel. The middle panel illustrates how random samples are drawn to the mode of the posterior distribution (lower panel) leading to faster convergence and higher effective sample size. Fig 14.1 in Kruschke [20].

bution  $p(y^{rep}|y)$ . Using the simulations of  $y^{rep}$  we can make various graphical displays comparing our observed data to the replications:

$$p(y^{rep}|y) = \int p(y^{rep}|\theta)p(\theta|y) d\theta \quad (4)$$

behind posterior predictive checking [57] in Figure 5, generated in our software package shinyStan [54]. Analogously, we will use predictive validation to adjust for overfitting of our model and perform a sensitivity analysis of our priors on key model parameters [19, 57].




Figure 5: Exploratory posterior predictive checking using our software shinyStan [54]: Visual comparison of the distribution of observed data (shaded in blue) to the distributions of the data simulated (thin lines) suggest a reasonable model fit.

**Computational Implementation:** We will implement the Bayesian model in parallel in the ultra-fast probabilistic programming language software STAN developed by my co-mentor Dr. Gelman [18]. Clever statistical transformations to sample in the standardized normal space will take full advantage of the faster convergence and higher effective sample size of STAN and overcome computational limitations of Bayesian hierarchical models for Big Data [19]. STAN is based on Hamiltonian Monte Carlo (HMC) [19], a Markov chain Monte Carlo (MCMC) algorithm, which avoids the sensitivity to correlated parameters that plague many MCMC methods by introducing auxiliary momentum variables [53] as illustrated in Figure 4. HMC is dependent on tuning the reciprocal relationship of the crucial parameters step size and desired number of steps. If the latter is too large, efficiency is low, if too small we see undesirable random walk behavior. To overcome this, Dr. Gelman's team developed and implemented the No-U-Turn Sampler (NUTS), a recursive algorithm to automate and optimize tuning the HMC [53].

**Model checking and comparison** We will look at auto-correlation, trace-plots and calculate the Gelman and Rubin's MCMC Convergence Diagnostic  $\hat{R}$  among others to evaluate the convergence of our Markov chain Monte Carlo (MCMC) simulations using shinyStan, the interactive visual application to explore and visualize Bayesian models, we developed [54]. In evaluating our Bayesian model's predictive performance, we will perform exploratory graphical [55] and confirmatory formal posterior predictive assessment using discrepancies [56] to compare the patient test set to simulated replications from our fitted hierarchical Bayesian model. For each draw of the estimated parameter  $\theta$  from the posterior  $p(\theta|y)$  we simulate data  $y^{rep}$  from the posterior predictive distribution  $p(y^{rep}|y)$ . Using the simulations of  $y^{rep}$  we can make various graphical displays comparing our observed data to the replications:

Equation (4) basically says, if our model is a good fit, then data generated by the model using the estimated parameters should have a distribution similar to the original data we observed. We illustrate this idea

**Model comparison** Assessing the plausibility of a posited model (and its assumptions) and comparing it to alternative models Cross-validation is widely used to compare statistical models for estimating out-of-sample prediction error, but for multi-level data, should the test set not have some hierarchical structure itself [58]?

We will compare our Bayesian Model to the frequentist algorithms using the minimum  $\chi^2$  discrepancy, essentially equivalent to the classical goodness-of-fit test statistic [56]. For additional validation and as a safeguard against over-fitting, we will train our model with patient data from other participating institutions (Mayo Clinic Rochester and Florida) and test if our model outperforms the classical prediction models even in other ecological settings, both if the classical frequentist model is based on data from all institutions or the test institution (say Mayo Clinic Rochester) alone.



We will compare models by parallel sampling [59]

**Technical approach** Boolean combinations of data matching and natural language processing of the prediction algorithms will be used to scan a real time copy of the hospital's clinical and administrative data including demographic, monitoring, pharmacy, laboratory, and physician notes for risk factors and physiological abnormality. Figure ?? illustrates the implementation algorithm. The rule engine (implemented in Java) will send out the alert to providers. We will integrate Bayesian patient triage into the infrastructure established during PROOFCheck, Dr. Gong's pragmatic trial, if we can show that our Bayesian prediction algorithm is superior to the existing algorithm. Based on our analysis for aim 2, compliance information will be reviewed for various items during the course of study so that sites could be targeted for re-education.

**Exploratory analysis** As an exploratory analysis, we will investigate if a deterioration over time improves prediction, in particular if it reduces false negative rates, in which case we shall incorporate it into our prediction algorithm.

### **We will advance Bayesian incomplete EMR-data imputation using auxiliary data**

Missing data are a characteristic limitation of large electronic medical records and may bias our prediction model [12]. Electronically medical records measurements not updated 24 hours earlier than the selected start time will be considered missing; as an illustrative example, we formulate a simplistic model illustrated in [Figure 3]. We combine the prediction of the dichotomous compound outcome  $Y$ , (defined as acute respiratory failure leading to mechanical ventilation and death) using latent arterial oxygen tension  $\Omega$  in a logistic regression model.

$$Y \sim Binom(\mu, n) \quad (5)$$

$$\mu = inv\_log(\beta_0 + \beta_1 * \Omega) \quad (6)$$

We may have the  $PaO_2$  from an arterial blood gas (ABG) or not. Nota bene, ABGs will certainly not be missing at random, but contingent on the  $PaO_2$  value and respiratory outcome  $Y$ . If the  $PaO_2$  from the ABG is observed, we will use it to predict the outcome  $Y$ . If no ABG was obtained, we impute the latent arterial oxygen tension  $\Omega$  with a regression model from the auxiliary data  $O_2$  Saturation and  $O_2$  therapy, formally:

$$\Omega = I(observed = true) * PaO_2 + I(observed = false) * \delta \quad (7)$$

$$\delta \sim Normal(\theta, \tau), \theta = \gamma_0 + \gamma_1 * O_2Sat + \gamma_2 * O_2Therapy \quad (8)$$

We will exploit the temporal relationship between variables in the longitudinal electronic medical records [60]. We will identify the auxiliary measure properties, ceiling and floor and potential threshold effects effects, test the imputations against manually verified data and published algorithms and compare them to the simple and multiple imputation strategies planned for Dr. Gong's pragmatic trial [61, 62]. We will perform posterior cross validation checks to investigate the appropriateness of our assumptions and incomplete data model [63].

### **Aim 2: To model temporality (institutional learning, seasons) and investigate provider compliance.**

To most closely reflect the realistic situation of actual real time academic and community medical delivery settings, we need to take temporal and seasonal changes changes into account. To focus education efforts and improve implementation of preventive or therapeutic measures, we need to consider and understand provider behavior.

**For specific Aim 2a,** to reflect changing risk profiles over time, we will adjust our Bayesian model to update continuously with new incoming patients and adapt our model to include temporal effects, like institutional learning , seasonal or endemic phenomena. We subsequently expand the model to include other regional institutions.

### **Aim 2b: Investigate compliance with the individual components of the checklist.**

During the second phase (PROOFCheck) of Dr. Gong's pragmatic trial, providers of a patient identified as high risk by the frequentist prediction algorithm will be prompted electronically to implement concrete preventive and corrective measures from a list of widely accepted interventions. During roll-out, providers receive targeted education on prevention and best practice. During PROOFCheck implementation, physician are notified by pager and/or electronic clinical interface; an interactive notification algorithm will suggest patient specific interventions from the checklist to the clinicians.

**Prediction of adverse events is useful only if followed by effective preventive action.** We will use data from this second phase of Dr. Gong's pragmatic trial to analyze provider fidelity and patient adherence with the proposed interventions. In particular, we will investigate which provider and patient characteristics predict compliance with which components of the intervention checklist. My project will be to investigate patient and provider characteristics as drivers of poor provider compliance in PROOFCheck, Dr. Gong's pragmatic trial. This will inform the ongoing PROOFCheck trial implementation, in which I will actively participate. Hence my concurrent results will immediately refocus our retraining efforts during PROOFCheck. Finally we will explore the individualization of preventive interventions using EMR-context.

**Population:** The population will be considerably smaller: Only data from those hospitalized adults identified by the frequentist algorithm developed during APPROVE as high risk for developing severe acute respiratory failure with prolonged mechanical ventilation and intubated patients will be included, during the second phase (PROOFCheck). We will include all data from all participating centers. Three institutions will contribute a total of 6 hospitals. Montefiore will include the 620-bed Moses Division, the 396-bed Weiler Hospital, and the 369-bed Wakefield Division. Together, they have 815 patients per year with acute respiratory failure. Mayo Clinic will contribute 2 hospitals from the Rochester campus: St Mary's hospital and Rochester Methodist Hospital, which together had 440 patients last year who required more than 2 days of mechanical ventilation. BIDMC will contribute its 646-bed hospital (including 440 medical/surgical and 77 ICU beds) which saw 2,204 mechanically ventilated patients last year. Patients chronically ventilated at home or who have Do not resuscitate orders, will be excluded. PROOFCheck will limit recruitment to wards found to have higher prevalence of severe adverse respiratory events during the first phase of Dr. Gong's trial (APPROVE).

**Exposures and predictors:** Provider and/or patient characteristics could be drivers of poor fidelity and adherence. We will consider time-invariant and time-variant provider and patient demographic and clinical data. We hypothesize two example of provider and patient demographics as predictors fidelity: (1) junior residents may be less comfortable with stricter blood transfusion triggers compared to seasoned physician assistant,; (2) providers fidelity with evidence based treatment recommendations may be contingent on patient gender, in particular in heart failure [64], likely an important predictor of acute respiratory failure in APPROVE. Time-variant patient characteristics (e.g. lab values) could determine provider fidelity; for example borderline blood hemoglobin concentration will likely influence compliance with blood transfusion recommendations issued during PROOFCheck.

**Outcomes: The unit of analysis is the triggered intervention.** The primary outcome will be provider compliance, a dichotomous event, defined as positive if the provider ordered the prompted preventive intervention. In order to measure and demonstrate compliance with the checklist, near real time (same day) transaction logs and evidence for compliance will be recorded through electronically.

**Study design and model building** This is a prospective observational cohort study to investigate sustained provider fidelity with EMR-triggered preventive interventions in PROOFCheck, Dr. Gong's pragmatic multicenter trial. We will build a Bayesian hierarchical multivariate logistic regression model of time-invariant and time-variant demographic, clinical and administrative variables, with levels for service, ward and institution, analogously to aim 1; the hierarchical structure is to reflect certain biases and attitudes ingrained in certain medical or surgical specialties or hospital wards, which may lead to different associations between provider and patient characteristics and provider fidelity with treatment prompts, for example service-specific reluctance to use triggers to minimize blood cell transfusion [65].

As an exploratory aim, we will attempt to individualize the suggested measures to make them more patient specific and measure the improved compliance with more patient-tailored prompts to the providers in preparation for subsequent pragmatic trials and grant applications. The patient's record will be scanned to provide context; for example, if the patient's mental status is undocumented, the clinician will be prompted with pertinent questions and preventive measure are proposed in accordance to those responses. As another example, prompts for evaluation of sedation breaks could be outputted only when continuous IV sedation is detected in the EMR. If we have time, we will also analyze predictors of the individual effectiveness of the various components of the intervention checklist.

## **Sustained implementation of our Bayesian algorithm with extension to other regional institutions.**

Beyond, PROOFCheck, we will continue to trigger individualized patient interventions to the providers in the Einstein system, if the EMR triggered intervention checklist proves to be effective. We will integrate our Bayesian model into the PROOFCheck infrastructure to sustain the outcome improvements, if our Bayesian imputation and prediction outperforms the classical algorithms. Finally, differences in regional health care environments predict patient, provider and institutional behavior and consequently outcomes, therefore risk patterns in one institution or even one region may not translate well to others; adjustments are surely necessary to translate our algorithms to different ecological settings. We will package and standardize our prediction model to tests its predictive power and offer its implementation at other regional institutions, for example our partners PROOFCheck and in the New York Clinical Research Data Network.

**Data collection, institutional review and data safety and monitoring board:** we will collect patient and provider characteristics and record provider compliance with EMR-triggered alerts in real time prospectively to investigate predictors of provider behavior in generalized linear models as described in more detail in aim 1. As detailed under aim 1, the IRB approved both APPROVE and PROOFCheck, including the data collection for provider compliance. We will apply for minor amendments of this IRB approval.

## **Timeline**

### **Limitations and feasibility of our research plan**

Our research plan is admittedly rather ambitious, but facilitated by its integration in APPROVE and PROOFCheck, my mentors ongoing pragmatic trials. This means that time consuming preliminary work like IRB approval, patient enrollment, computerized data collection, data cleaning, aggregation and standardization, preliminary identification of important predictors of respiratory failure are already under way and well funded. The computability of our complex Bayesian model hinges on the witty statistical formulation and transformations of our hierarchical models and their effective computational implementation. Fortunately, this is exactly my co-mentor, Dr. Gelman's expertise and he is personally invested in the realization of complex Bayesian models like mine. Even if we were unable to implement a simple coherent hierarchical in the end, other independent components of my research proposal alone will lead to high impact publications; for example developing new missing data imputation using auxiliary data for incomplete electronic medical records will attract attention and there is considerable interest in a better understanding of poor provider compliance in clinical trials.

### **My research thrust is well aligned with NIH funding opportunities and emerging paradigms**

Together with my mentors Dr. Gong, Gelman and Hall, we are working on an aligned R01 applications to the BD2K initiative in response to FAO PA-14-156. We propose to further develop Bayesian computational algorithms for the software STAN, using Dr. Gong's trial as use case. My proposed K01 mentored research training will give me the competitive edge and expertise to lead this or similar multi-disciplinary NIH applications as principle investigator. The biostatistics Ph.D. from the prestigious Columbia Mailman School of Public Health will give me added credibility and the preferential status as early stage investigator. Entering the wide-open field of Bayesian hierarchical modeling for electronic medical records at its dawn with such a rigorous training will give me a leg up to establish myself as a leading investigator, while this unique expertise makes me a desirable collaborator and key player in my own institution, specially the development of electronic medical record surveillance at Montefiore Hospital. I am particularly interested to extend our Bayesian prediction and prevention tools to long-term perioperative surgical outcomes, incorporating record matching across different databases. This is very well aligned with departmental and institutional priorities, my prior work in long-term outcomes [66] and the emergent paradigm in my specialty, the "Perioperative Surgical Home" [67] as well as our integration of research data across regional academic institutions [68].

## References

- [1] S. Yu, S. Leung, M. Heo, G. J. Soto, R. T. Shah, S. Gunda, and M. N. Gong. Comparison of risk prediction scoring systems for ward patients: a retrospective nested case-control study. *Crit Care*, 18(3):R132, 2014. PMID: 24970344.
- [2] H. Wunsch, W. T. Linde-Zwirble, D. C. Angus, M. E. Hartman, E. B. Milbrandt, and J. M. Kahn. The epidemiology of mechanical ventilation use in the United States. *Crit Care Med*, 38(10):1947–1953, Oct 2010. PMID: 20639743.
- [3] V. M. Ranieri, F. Giunta, P. M. Suter, and A. S. Slutsky. Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. *JAMA*, 284(1):43–44, Jul 2000. PMID: 10872010.
- [4] J. M. Rohde, A. J. Odden, C. Bonham, L. Kuhn, P. N. Malani, L. M. Chen, S. A. Flanders, and T. J. Iwashyna. The epidemiology of acute organ system dysfunction from severe sepsis outside of the intensive care unit. *J Hosp Med*, 8(5):243–247, May 2013. PMID: 23401431.
- [5] M. S. Herridge, A. M. Cheung, C. M. Tansey, A. Matte-Martyn, N. Diaz-Granados, F. Al-Saidi, A. B. Cooper, C. B. Guest, C. D. Mazer, S. Mehta, T. E. Stewart, A. Barr, D. Cook, A. S. Slutsky, and C. C. C. T. G. . One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med*, 348(8):683–693, Feb 2003. PMID: 12594312.
- [6] K. M. Hillman, P. J. Bristow, T. Chey, K. Daffurn, T. Jacques, S. L. Norman, G. F. Bishop, and G. Simmons. Duration of life-threatening antecedents prior to intensive care admission. *Intensive Care Med*, 28(11):1629–1634, Nov 2002. PMID: 12415452.
- [7] P. McQuillan, S. Pilkington, A. Allan, B. Taylor, A. Short, G. Morgan, M. Nielsen, D. Barrett, G. Smith, and C. H. Collins. Confidential inquiry into quality of care before admission to intensive care. *BMJ*, 316(7148):1853–1858, Jun 1998. PMID: 9632403.
- [8] N. Naeem and H. Montenegro. Beyond the intensive care unit: a review of interventions aimed at anticipating and preventing in-hospital cardiopulmonary arrest. *Resuscitation*, 67(1):13–23, Oct 2005. PMID: 16150531.
- [9] E. Rivers, B. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, E. Peterson, M. Tomlanovich, and E. G.-D. T. C. G. . Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*, 345(19):1368–1377, Nov 2001. PMID: 11794169.
- [10] E. P. Rivers. Early goal-directed therapy in severe sepsis and septic shock: converting science to reality. *Chest*, 129(2):217–218, Feb 2006. PMID: 16478830.
- [11] I. A. Mitchell, H. McKay, C. Van Leuvan, R. Berry, C. McCutcheon, B. Avar, N. Slater, T. Neeman, and P. Lamberth. A prospective controlled trial of the effect of a multi-faceted intervention on early recognition and intervention in deteriorating hospital patients. *Resuscitation*, 81(6):658–666, Jun 2010. PMID: 20378235.
- [12] B. B. Dean, J. Lam, J. L. Natoli, Q. Butler, D. Aguilar, and R. J. Nordyke. Review: use of electronic medical records for health outcomes research: a literature review. *Med Care Res Rev*, 66(6):611–638, Dec 2009. PMID: 19279318.
- [13] R. Amarasingham, B. J. Moore, Y. P. Tabak, M. H. Drazner, C. A. Clark, S. Zhang, W. G. Reed, T. S. Swanson, Y. Ma, and E. A. Halm. An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. *Med Care*, 48(11):981–988, Nov 2010. PMID: 20940649.
- [14] M. Bayes and M. Price. An essay towards solving a problem in the doctrine of chances. by the late rev. mr. bayes, frs communicated by mr. price, in a letter to john canton, amfrs. *Philosophical Transactions (1683-1775)*, pages 370–418, 1763.

- [15] D. Ashby. Bayesian statistics in medicine: a 25 year review. *Stat Med*, 25(21):3589–3631, Nov 2006. PMID: 16947924.
- [16] D. J. Spiegelhalter, J. P. Myles, D. R. Jones, and K. R. Abrams. Bayesian methods in health technology assessment: a review. *Health Technol Assess*, 4(38):1–130, 2000. PMID: 11134920.
- [17] C. Yoo, L. Ramirez, and J. Liuzzi. Big data analysis using modern statistical and machine learning methods in medicine. *Int Neurol J*, 18(2):50–57, Jun 2014. PMID: 24987556.
- [18] Stan Development Team. Stan: A C++ Library for Probability and Sampling, Version 2.5.0, 2014.
- [19] A. Gelman, J. B. Carlin, H. S. Stern, and D. B. Rubin. *Bayesian data analysis*, volume 2. Taylor & Francis, 2014.
- [20] J. Kruschke. *Doing Bayesian data analysis: A tutorial introduction with R*. Academic Press, 2014.
- [21] J. K. Kruschke. Bayesian estimation supersedes the t test. *J Exp Psychol Gen*, 142(2):573–603, May 2013. PMID: 22774788.
- [22] K. Abrams and B. Sansó. Approximate Bayesian inference for random effects meta-analysis. *Stat Med*, 17(2):201–218, Jan 1998. PMID: 9483729.
- [23] J. Bafumi and A. Gelman. Fitting Multilevel Models When Predictors and Group Effects Correlate. SSRN Scholarly Paper ID 1010095, Social Science Research Network, Rochester, NY, September 2007.
- [24] J. B. Carlin. Meta-analysis for 2 x 2 tables: a Bayesian approach. *Stat Med*, 11(2):141–158, Jan 1992. PMID: 1349763.
- [25] A. J. Sutton, N. J. Cooper, K. R. Abrams, and A. Ades. *Evidence synthesis for decision making in healthcare*, volume 132. John Wiley & Sons, 2012.
- [26] A. Gelman. *Red state, blue state, rich state, poor state: why Americans vote the way they do*. Princeton University Press, 2009.
- [27] A. Gelman. Multilevel (Hierarchical) Modeling: What It Can and Cannot Do. *Technometrics*, 48(3):432–435, August 2006.
- [28] D. B. Rubin. Inference and missing data. *Biometrika*, 63(3):581–592, 1976.
- [29] C. B. Hall, R. B. Lipton, M. J. Katz, and C. Wang. Correcting Bias Caused by Missing Data in the Estimate of the Effect of Apolipoprotein epsilon 4 on Cognitive Decline. *J Int Neuropsychol Soc*, pages 1–6, Nov 2014. PMID: 25389642.
- [30] M. J. Daniels, C. Wang, and B. H. Marcus. Fully Bayesian inference under ignorable missingness in the presence of auxiliary covariates. *Biometrics*, 70(1):62–72, Mar 2014. PMID: 24571539.
- [31] C. Wang and C. B. Hall. Correction of bias from non-random missing longitudinal data using auxiliary information. *Stat Med*, 29(6):671–679, Mar 2010. PMID: 20029935.
- [32] X.-L. Meng. Multiple-Imputation Inferences with Uncongenial Sources of Input. *Statist. Sci.*, 9(4):538–558, 11 1994.
- [33] L. M. Collins, J. L. Schafer, and C. M. Kam. A comparison of inclusive and restrictive strategies in modern missing data procedures. *Psychol Methods*, 6(4):330–351, Dec 2001. PMID: 11778676.
- [34] D. B. Rubin. Multiple imputation after 18+ years. *Journal of the American Statistical Association*, 91(434):473–489, 1996.

- [35] M. J. Daniels and J. W. Hogan. *Missing data in longitudinal studies: Strategies for Bayesian modeling and sensitivity analysis*. CRC Press, 2008.
- [36] J. L. Schafer. *Analysis of incomplete multivariate data*. CRC press, 1997.
- [37] G. Fitzmaurice, M. Davidian, G. Verbeke, and G. Molenberghs. *Longitudinal data analysis*. CRC Press, 2008.
- [38] M. M. Duncan, P. A. McIntosh, C. D. Stayton, and C. B. Hall. Individualized performance feedback to increase prenatal domestic violence screening. *Matern Child Health J*, 10(5):443–449, Sep 2006. PMID: 16710766.
- [39] D. A. Davis, M. A. Thomson, A. D. Oxman, and R. B. Haynes. Changing physician performance. A systematic review of the effect of continuing medical education strategies. *JAMA*, 274(9):700–705, Sep 1995. PMID: 7650822.
- [40] M. Campbell, R. Fitzpatrick, A. Haines, A. L. Kinmonth, P. Sandercock, D. Spiegelhalter, and P. Tyrer. Framework for design and evaluation of complex interventions to improve health. *BMJ*, 321(7262):694–696, Sep 2000. PMID: 10987780.
- [41] B. S. Mittman. Creating the evidence base for quality improvement collaboratives. *Ann Intern Med*, 140(11):897–901, Jun 2004. PMID: 15172904.
- [42] R. E. Glasgow and K. M. Emmons. How can we increase translation of research into practice? Types of evidence needed. *Annu Rev Public Health*, 28:413–433, 2007. PMID: 17150029.
- [43] P. Selby, G. Brosky, P. I. Oh, V. Raymond, and S. Ranger. How pragmatic or explanatory is the randomized, controlled trial? The application and enhancement of the PRECIS tool to the evaluation of a smoking cessation trial. *BMC Med Res Methodol*, 12:101, 2012. PMID: 22824225.
- [44] G. Tosh, K. Soares-Weiser, and C. E. Adams. Pragmatic vs explanatory trials: the pragmascope tool to help measure differences in protocols of mental health randomized controlled trials. *Dialogues Clin Neurosci*, 13(2):209–215, 2011. PMID: 21842618.
- [45] H. E. Kenz and P. Van der Linden. Transfusion-related acute lung injury. *Eur J Anaesthesiol*, 31(7):345–350, Jul 2014. PMID: 24892308.
- [46] P. C. Hébert, G. Wells, M. A. Blajchman, J. Marshall, C. Martin, G. Pagliarello, M. Tweeddale, I. Schweitzer, and E. Yetisir. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*, 340(6):409–417, Feb 1999. PMID: 9971864.
- [47] M. Ranucci, U. Di Dedda, S. Castelveccchio, L. Menicanti, A. Frigiola, G. Pelissero, S. , and C. O. R. S. Group. Impact of preoperative anemia on outcome in adult cardiac surgery: a propensity-matched analysis. *Ann Thorac Surg*, 94(4):1134–1141, Oct 2012. PMID: 22698773.
- [48] Practice guidelines for perioperative blood management: an updated report by the american society of anesthesiologists task force on perioperative blood management. *Anesthesiology*, 122(2):241–275, Feb 2015. PMID: 25545654.
- [49] D. S. Likosky, D. C. FitzGerald, R. C. Groom, D. K. Jones, R. A. Baker, K. G. Shann, C. D. Mazer, B. D. Spiess, and S. C. Body. Effect of the perioperative blood transfusion and blood conservation in cardiac surgery clinical practice guidelines of the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists upon clinical practices. *Anesth Analg*, 111(2):316–323, Aug 2010. PMID: 20488928.
- [50] C. H. Weiss, F. Moazed, C. A. McEvoy, B. D. Singer, I. Szleifer, L. A. N. Amaral, M. Kwasny, C. M. Watts, S. D. Persell, D. W. Baker, J. I. Sznajder, and R. G. Wunderink. Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study. *Am J Respir Crit Care Med*, 184(6):680–686, Sep 2011. PMID: 21616996.



- [51] H.-B. Rothenhäusler, B. Grieser, G. Nollert, B. Reichart, G. Schelling, and H.-P. Kapfhammer. Psychiatric and psychosocial outcome of cardiac surgery with cardiopulmonary bypass: a prospective 12-month follow-up study. *Gen Hosp Psychiatry*, 27(1):18–28, 2005. PMID: 15694215.
- [52] M. Rotte, C. Baerecke, G. Pottag, S. Klose, E. Kanneberg, H.-J. Heinze, and H. Lehnert. Insulin affects the neuronal response in the medial temporal lobe in humans. *Neuroendocrinology*, 81(1):49–55, 2005. PMID: 15809512.
- [53] M. D. Homan and A. Gelman. The no-U-turn sampler: Adaptively setting path lengths in Hamiltonian Monte Carlo. *The Journal of Machine Learning Research*, 15(1):1593–1623, 2014.
- [54] shinyStan Team. shinyStan: R Package for Interactive Exploration of Markov Chain Monte Carlo Output, Version 0.1, 2015.
- [55] A. Gelman. Exploratory data analysis for complex models. *Journal of Computational and Graphical Statistics*, 13(4), 2004.
- [56] A. Gelman, X.-L. Meng, and H. Stern. Posterior predictive assessment of model fitness via realized discrepancies. *Statistica sinica*, 6(4):733–760, 1996.
- [57] A. Gelman, Y. Goegebeur, F. Tuerlinckx, and I. Van Mechelen. Diagnostic Checks for Discrete Data Regression Models Using Posterior Predictive Simulations. *Applied Statistics*, pages 247–268, 2000.
- [58] W. Wang and A. Gelman. Difficulty of selecting among multilevel models using predictive accuracy, 2014.
- [59] P. Congdon. Bayesian predictive model comparison via parallel sampling. *Computational statistics & data analysis*, 48(4):735–753, 2005.
- [60] C. A. Welch, I. Petersen, J. W. Bartlett, I. R. White, L. Marston, R. W. Morris, I. Nazareth, K. Walters, and J. Carpenter. Evaluation of two-fold fully conditional specification multiple imputation for longitudinal electronic health record data. *Stat Med*, 33(21):3725–3737, Sep 2014. PMID: 24782349.
- [61] J. L. Huntington and A. Dueck. Handling missing data. *Curr Probl Cancer*, 29(6):317–325, 2005. PMID: 16311133.
- [62] J. A. Sloan and A. Dueck. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. *J Biopharm Stat*, 14(1):73–96, Feb 2004. PMID: 15027501.
- [63] A. Gelman, G. King, and C. Liu. Not asked and not answered: Multiple imputation for multiple surveys. *Journal of the American Statistical Association*, 93(443):846–857, 1998.
- [64] J. L. Cook, K. L. Grady, M. Colvin, S. M. Joseph, M. A. Brisco, M. N. Walsh, and f. t. g. A. D. W. G. . Sex Differences in the Care of Patients With Advanced Heart Failure. *Circ Cardiovasc Qual Outcomes*, Feb 2015. PMID: 25714825.
- [65] L. T. Goodnough, J. H. Levy, and M. F. Murphy. Concepts of blood transfusion in adults. *Lancet*, 381(9880):1845–1854, May 2013. PMID: 23706801.
- [66] M. H. Andreae and D. A. Andreae. Regional anaesthesia to prevent chronic pain after surgery: a Cochrane systematic review and meta-analysis. *Br J Anaesth*, 111(5):711–720, Nov 2013. PMID: 23811426.
- [67] T. R. Vetter, A. M. Boudreaux, K. A. Jones, J. M. Hunter, Jr, and J.-F. Pittet. The perioperative surgical home: how anesthesiology can collaboratively achieve and leverage the triple aim in health care. *Anesth Analg*, 118(5):1131–1136, May 2014. PMID: 24781579.

- [68] R. Kaushal, G. Hripcsak, D. D. Ascheim, T. Bloom, T. R. Campion, Jr, A. L. Caplan, B. P. Currie, T. Check, E. L. Deland, M. N. Gourevitch, R. Hart, C. R. Horowitz, I. Kastenbaum, A. A. Levin, A. F. H. Low, P. Meissner, P. Mirhaji, H. A. Pincus, C. Scaglione, D. Shelley, J. N. Tobin, and N. Y. C.-C. D. R. N. . Changing the research landscape: the New York City Clinical Data Research Network. *J Am Med Inform Assoc*, 21(4):587–590, 2014. PMID: 24821739.